- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT04750382
A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer
8. februar 2021 oppdatert av: Taizhou Hanzhong biomedical co. LTD
A Single-armed Multicenter Phase Ib / II Study of HX008 (a Recombinant Humanized Anti-PD-1 Monoclonal Antibody) Combined With GP Regimen as the First-line Treatment in Patients With Metastatic Triple Negative Breast Cancer
HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.
In this study, the safety and preliminary efficacy of HX008+cisplatin+gemcitabine for the treatment of patients with metastatic triple-negative breast cancer will be evaluated.
Studieoversikt
Status
Aktiv, ikke rekrutterende
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
31
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Shanghai
-
Shanghai, Shanghai, Kina
- Fudan University Shanghai Cancer Center
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år til 70 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Provide written informed consent voluntarily. Understand this protocol and be willing and able to adhere to the study visit schedule.
- Age 18-70 years old, male or female.
- Diagnosed with stage IV or recurrent or metastatic TNBC who are not suitable for surgical treatment.
- Histopathology shows that ER, PR and HER-2 are all negative. If metastasis exists, the histopathology result of metastasis is preferred. ER and PR negative are defined as ER < 1% and PR < 1%. HER-2 negative is defined as HER-2 (-) or (+) in immunohistochemical test. For HER-2 (++), additional negative result should be observed in FISH test. For HER-2 (-) or (+), FISH test is optional, but the result should be negative.
- Have not been treated with any chemotherapy drugs for recurrent and metastatic triple negative breast cancer (adjuvant / neoadjuvant therapy is allowed, if the time between the last dose of drug and recurrence or metastasis is more than 6 months).
- Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Score.
- Life expectancy ≥ 3 months.
- Has at least one measurable extracranial lesion according to RECIST1.1, which has not been treated with radiotherapy.
Has sufficient organ and bone marrow function to meet the following laboratory examination standards:
- Blood routine: absolute neutrophil count (ANC)≥1.5×10^9/L; while blood cell count (WBC)≥3×10^9/L; platelet count (PLT)≥100×10^9/ L; hemoglobin (HGB)≥90 g/L (without blood transfusion within 14 days prior to enrollment);
- Renal function: serum creatinine (Scr) ≤1.5×ULN, and endogenous creatinine clearance is more than 50 ml / min (Cockcroft Gault formula);
- Liver function: TBIL≤1.5×ULN; Patients without liver metastases require alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5× ULN. Patients with liver metastases require: ALT and AST≤5×ULN;
- The coagulation function is adequate, which is defined as the international normalized ratio (INR) ≤ 2×ULN; or activated partial thromboplastin time (APTT)≤ 1.5×ULN (except for those who are receiving anticoagulant therapy if their PT/APTT are within the expected values);
- Reproductive men and women of childbearing age are willing to take effective contraceptive measures (such as oral contraceptives, intrauterine contraceptives, sexual abstinence or barrier contraceptives combined with spermicide) from signing the informed consent form to 12 months after the last administration of the trial drug.
Exclusion Criteria:
- Suffered from other malignant tumors in the past 5 years, except carcinoma in situ from cervix or skin basal cell carcinoma that has been cured.
- With adverse reactions of previous treatment that have not be recovered to CTCAE V5.0 grade ≤ 1, except for the residual hair loss effect.
- Had prior treatment with any anti-PD-1, PD-L1 or CTLA-4 therapies.
- Participants with active or a history of autoimmune diseases that probably will recur (e.g. systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, autoimmune thyroid disease, multiple sclerosis, vasculitis, glomerulitis, etc.), or with high risk (e.g. organ transplantation requiring immunosuppressive therapy). However, participants with the following diseases are eligible: skin diseases requiring no systemic treatment (such as eczema, skin rash covering less than 10% of the body surface, psoriasis without ophthalmic symptoms, etc.).
- Expected to undergo major surgery during the study treatment or within 28 days before the first administration of the study drug (excluding surgery for diagnostic purpose).
- Need to receive systemic corticosteroids (dose equivalent to > 10 mg prednisone / day) or other immunosuppressive drugs within 14 days before enrollment or during the study period. Those under the following conditions are eligible: a) Locally external use or inhaled corticosteroids; b) short-term (≤ 7 days) use of glucocorticoids for the prevention or treatment of non-autoimmune allergic diseases.
- Has active digestive ulcer, incomplete intestinal obstruction, active gastrointestinal hemorrhage or perforation.
- Has active interstitial pneumonia, pulmonary fibrosis, acute pulmonary disorders, acute radiation pneumonitis, et al.
- Has uncontrolled systemic diseases, such as cardiovascular and cerebrovascular diseases (unstable angina pectoris, etc.), diabetes, hypertension, tuberculosis, etc;
- Has a history of HIV infection, or other acquired or innate immune deficiency disorders, or a history of organ or stem-cell transplantation.
- Has active chronic HBV or HCV infection, except those with HBV DNA viral load ≤500 IU/mL or <10^3 copies/mL, or HCV RNA negative after adequate treatment.
- Has severe infection within 4 weeks or active infection requiring IV infusion or oral administration of antibiotics within 2 weeks prior to the first dose of the study drug.
- Known to be allergic to macromolecular protein agents or monoclonal antibody; Known to has a history of severe allergies (CTCAE v5.0 ≥ grade 3) to any of the components in the study drug.
- Has participated in other clinical trial within 4 weeks before the first administration of the study drug.
- Alcohol dependence or drug abuse within recent one year.
- Has a history of confirmed neurological or mental disorders, such as epilepsy, dementia; or with poor compliance; or the presence of peripheral neurological disorders.
- Has symptomatic central nervous system metastasis.
- Participants with asymptomatic central nervous system metastasis with or without treatment, who have no disease progression by CT / MRI examination, and whose interval from the last radiotherapy is more than 4 weeks, can be enrolled.
- Participants with uncontrollable pleural effusion, peritoneal effusion or pericardial effusion requiring repeated drainage within 7 days before enrollment.
- Participants who had received hematopoietic stimulating factors such as colony stimulating factor and erythropoietin within 2 weeks prior to the first dose of study drug
- Is pregnant or breastfeeding.
- Other reasons disqualifying the entering of this study based on the evaluation of the investigators.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: HX008+Cisplatin+Gemcitabine
|
Participants will receive HX008 3mg/kg, Day 1,Q3W for up to 2 years + Cisplatin 75mg/m^2, Day 1, Q3W for up to 6 cycles +Gemcitabine 1250mg/m^2, Day 1, Day 8, Q3W for up to 6 cycles
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Antall deltakere med behandlingsrelaterte uønskede hendelser vurdert av CTCAE v5.0
Tidsramme: 24 måneder
|
24 måneder
|
|
1-year progression-free survival rate
Tidsramme: 24 months
|
The rate of participants who neither experience disease progression nor death
|
24 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Objective Response Rate (ORR)
Tidsramme: 12 months
|
Percentage of subjects achieving complete response (CR) and partial response (PR) according to RECIST1.1 and iRECIST.
|
12 months
|
Duration of Response (DOR)
Tidsramme: 24 months
|
Disease Control Rate (DCR) refers to the proportion of subjects who achieve CR, PR and SD through imaging evaluation.
|
24 months
|
Overall survival (OS)
Tidsramme: 24 months
|
Overall survival (OS) refers to the time from the first study drug treatment to death due to any cause.
|
24 months
|
Progresjonsfri overlevelse (PFS)
Tidsramme: 24 måneder
|
Progresjonsfri overlevelse (PFS) er definert som tiden fra første studie medikamentell behandling til sykdomsprogresjon (PD) eller til pasientens død på grunn av en hvilken som helst årsak.
|
24 måneder
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Etterforskere
- Studiestol: Xichun Hu, Fudan University
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
15. juli 2019
Primær fullføring (Faktiske)
1. desember 2020
Studiet fullført (Forventet)
1. desember 2021
Datoer for studieregistrering
Først innsendt
8. februar 2021
Først innsendt som oppfylte QC-kriteriene
8. februar 2021
Først lagt ut (Faktiske)
11. februar 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
11. februar 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
8. februar 2021
Sist bekreftet
1. februar 2021
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Hudsykdommer
- Neoplasmer
- Neoplasmer etter nettsted
- Bryst sykdommer
- Brystneoplasmer
- Trippel negative brystneoplasmer
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Antivirale midler
- Enzymhemmere
- Antimetabolitter, antineoplastisk
- Antimetabolitter
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Gemcitabin
Andre studie-ID-numre
- HX008-Ib/II-TNBC-01
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Trippel-negativ brystkreft
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UkjentHR-positiv, HER2-negativ og PIK3CA Mutation Advanced Breast CancerKina
Kliniske studier på HX008+Cisplatin+Gemcitabine
-
Taizhou Hanzhong biomedical co. LTDHar ikke rekruttert ennåAnaplastisk kreft i skjoldbruskkjertelenKina
-
Kansai Hepatobiliary Oncology GroupFullført
-
Taizhou Hanzhong biomedical co. LTDRekruttering
-
Taizhou Hanzhong biomedical co. LTDUkjent
-
Taizhou Hanzhong biomedical co. LTDUkjent
-
3D Medicines (Sichuan) Co., Ltd.Har ikke rekruttert ennåNeoplasmer i galleveiene
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial... og andre samarbeidspartnereAktiv, ikke rekrutterendeNasofaryngealt karsinom | Nasofaryngeale neoplasmer | Nasofaryngeale sykdommer | Neoplasma i hode og nakkeKina
-
Shanghai Miracogen Inc.RekrutteringAvanserte solide svulsterKina
-
Shanghai Miracogen Inc.RekrutteringEn studie av MRG002 i behandling av pasienter med HER2-uttrykte avanserte ondartede solide svulster.Avanserte ondartede solide svulsterKina
-
Taizhou HoudeAoke Biomedical Co., Ltd.Ukjent